Stratifying patients by a cutoff ARAMW score of 0.6 (selected due to its ability to stratify patients with distinct outcomes), we observed that patients with high (>0.6) ARAMW scores exhibited greater PSA responses (P = 0.010) (Figure 3D), greater decrease in tumor volume (P = 0.005) (Figure 3E), a trend toward longer radiographic progression-free survival (P = 0.058) (Figure 3F), and longer overall survival (P = 0.002) (Figure 3G) on BAT. This evidence concerns the gene KLK3 and neoplasm.